INCATE receives Lighthouse Award 2024 from Swiss National Science Foundation
The INCATE management team and Christoph Dehio from the INCATE Board, here at the AMR Conference 2024 in Basel. From left to right: Derry Mercer (Bioaster), Sina Gerbach (Leibniz-HKI), Helmut Kessmann (Univ. Basel), Mercedes Gonzalez Moreno (Leibniz-HKI), Ina-Kristin Behrens (DZIF), Silke Alt (DZIF), Doug Häggström (Univ. Basel), Helena Costa Pereira (Leibniz-HKI), Christoph Dehio (Univ. Basel), Peter Seiler (Leibniz-HKI).
INCATE, the INCubator for Antimicrobial Therapies in Europe co-founded by the German Center for Infection Research, has been honoured with the 2024 Lighthouse Award for outstanding Transfer of Knowledge and Technology by the Swiss National Science Foundation. The award ceremony took place on 27 June in Bern, Switzerland.
The Swiss National Science Foundation (SNSF) has developed the Lighthouse Awards to recognise the quality of non-science initiatives such as promoting equal opportunity, the transfer of knowledge and technologies, open science initiatives, communication of science, and education.
Among five Swiss National Centres of Competence in Research (NCCRs) honoured for their initiatives outside science, the NCCR AntiResist was recognised for INCATE, an entrepreneurial incubator combating antibiotic resistance. According to the SNSF, “INCATE—where the NCCR AntiResist is one of the founding members—wins the Lighthouse Award for the transfer of technologies. INCATE plays a key role in addressing antimicrobial resistance (AMR), bringing together scientists and specialists from industry to trigger the development of new solutions to combat AMR. Worldwide, AMR causes more than a million of deaths each year, as the evolution of bacteria renders current antibiotics ineffective. In addition, research is stagnating as the development of antibiotics is not profitable. The INCATE initiative seeks to change this with its collaborative approach, providing advice, networking opportunities and financing, thereby creating a genuine international community of interest. In three years, INCATE established strong links between the biopharmaceutical industry, European institutions and innovators from academia to fill the pipeline with new antibiotics.”
“Let me express, on behalf of the entire INCATE team, how honoured we feel receiving this award," said Helmut Kessmann from INCATE’s Management team. "The SNSF and NCCR AntiResist Management supported INCATE’s creative design and implementation from its inception, with the objective of creating an international and impactful organisation. Since 2021, we have helped innovators turn university findings into start-up businesses. We would also like to express a big thank you to the two other founding institutions, the German Center for Infection Research (DZIF) and the Leibniz:HKI as well as our Selection Committee, who play a crucial role in selecting the most promising enterprises.”
This award will allow INCATE to continue its commitment to advancing novel and breakthrough technologies and new products to fight the antibiotic resistance challenge.
About INCATE
INCATE—the INCubator for Antimicrobial Therapies in Europe—is a not-for-profit partnership which brings together translational and basic research, industry, experienced entrepreneurs and investors from across Europe and beyond. The German Center for Infection Research (DZIF), the Leibniz:HKI (part of Leibniz Association) in Germany, the Swiss National Centre of Competence in Research (NCCR) AntiResist and the University of Basel are the academic founding members of INCATE with the University of Basel acting as the host. Together with the four industry partners Boehringer Ingelheim, Roche, Shionogi and MSD as well as other organisations, funders and investors, INCATE want to ensure that the pipeline of new antibiotics and technology platforms is filled and strengthened.
Since 2021, INCATE has been contacted by over 280 start-ups and projects, gathering more than 118 applications. The establishment of a robust pipeline for new ventures has been a hallmark accomplishment, along with furnishing essential support to 33 ventures at Stage I. The current portfolio of Stage I ventures comes from 16 countries so far, with over half not founded as companies when they first contacted INCATE. The technologies selected include traditional direct acting small molecules and peptides but also phages, anti-virulence and other technologies. Notably, two of these ventures moved forward to Stage II. At present, the landscape includes some INCATE ventures that have achieved the coveted “investable stage” status, successfully securing equity investment and forging impactful collaborations. Some success stories from our portfolio include Invitris, smartbax, CC Bio, Disperazol, and Xiretsa.
About NCCR AntiResist
The National Center of Competence in Research (NCCR) AntiResist is a Swiss research consortium funded by the Swiss National Science Foundation (SNSF), which aims to tackle the urgent global imperative of antimicrobial resistance (AMR), one of the top ten threats to global health. AntiResist is a diverse panel of experts in the fields of clinical research, infection biology, and engineering, which aims at transforming the research and development of new antibiotics and antimicrobial strategies by building human tissue-based infection models to screen and discover new antibiotics.
About SNSF
Based on a government mandate, the Swiss National Science Foundation (SNSF) supports scientific research in all academic disciplines—from physics to medicine to sociology. At the end of 2022, the SNSF was funding 5500 projects involving more than 20,000 researchers. This makes us the leading Swiss organisation for the promotion of scientific research.
In close collaboration with higher education institutions and other partners, the SNSF strives to create the best possible conditions for the development and global interconnectedness of Swiss research. It pays particular attention to the promotion of early-career researchers. In addition, it accepts evaluation mandates to help ensure that large third-party-funded research initiatives deliver the highest scientific quality. The Lighthouse Awards were created to recognise the quality of non-science initiatives such as promoting equal opportunity, the transfer of knowledge and technologies, open science initiatives, communication of science, and education.
Source: Press releases of INCATE and the Swiss National Science Foundation.
